The Federal Drug Administration has cleared wireless integration between Johnson & Johnson’s OneTouch Verio Flex monitoring system and WellDoc’s BlueStar diabetes management platform via Bluetooth capability. BlueStar will use the data to provide a personalized and real-time feedback to consumers and offer virtual coaching for a complete treatment plan. BlueStar will also let physicians make treatment management decisions based on that real-time data. Consumers can access this management solution through a mobile app or a website.
The BlueStar app requires a prescription to download, but is otherwise free to consumers.
Johnson & Johnson has brought innovative, collaborative health and well-being products and solutions to the public for more than 130 years.
Welldoc is a company committed to providing innovative mobile technology solutions that integrate with the health care system to help consumers manage type 2 diabetes on a day-to-day basis.
This was reported by FierceBiotech on December 14, 2016.